eprintid: 10056847
rev_number: 22
eprint_status: archive
userid: 608
dir: disk0/10/05/68/47
datestamp: 2018-09-26 13:43:11
lastmod: 2021-10-10 22:31:14
status_changed: 2018-09-26 13:43:11
type: article
metadata_visibility: show
creators_name: Teunissen, CE
creators_name: Otto, M
creators_name: Engelborghs, S
creators_name: Herukka, S-K
creators_name: Lehmann, S
creators_name: Lewczuk, P
creators_name: Lleó, A
creators_name: Perret-Liaudet, A
creators_name: Tumani, H
creators_name: Turner, MR
creators_name: Verbeek, MM
creators_name: Wiltfang, J
creators_name: Zetterberg, H
creators_name: Parnetti, L
creators_name: Blennow, K
title: White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Society, Education Biomarkers, Neurology, Cerebrospinal fluid, Body fluids, Biomarker discovery, Assay development, Clinical implementation
note: © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
abstract: Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer’s disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development. The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium. The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.
date: 2018-12
date_type: published
publisher: BIOMED CENTRAL LTD
official_url: https://doi.org/10.1186/s13195-018-0359-x
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
article_type_text: Journal Article
verified: verified_manual
elements_id: 1544612
doi: 10.1186/s13195-018-0359-x
language_elements: English
lyricists_name: Zetterberg, Henrik
lyricists_id: HZETT94
actors_name: Bracey, Alan
actors_id: ABBRA90
actors_role: owner
full_text_status: public
publication: Alzheimer's Research & Therapy
volume: 10
number: 1
article_number: 30
pages: 8
issn: 1758-9193
citation:        Teunissen, CE;    Otto, M;    Engelborghs, S;    Herukka, S-K;    Lehmann, S;    Lewczuk, P;    Lleó, A;                                 ... Blennow, K; + view all <#>        Teunissen, CE;  Otto, M;  Engelborghs, S;  Herukka, S-K;  Lehmann, S;  Lewczuk, P;  Lleó, A;  Perret-Liaudet, A;  Tumani, H;  Turner, MR;  Verbeek, MM;  Wiltfang, J;  Zetterberg, H;  Parnetti, L;  Blennow, K;   - view fewer <#>    (2018)    White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.                   Alzheimer's Research & Therapy , 10  (1)    , Article 30.  10.1186/s13195-018-0359-x <https://doi.org/10.1186/s13195-018-0359-x>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10056847/1/Zetterberg_White%20paper%20by%20the%20Society%20for%20CSF%20Analysis%20and%20Clinical%20Neurochemistry.%20Overcoming%20barriers%20in%20biomarker%20development%20and%20clinical%20translation_VoR.pdf